Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) was up 6.9% during mid-day trading on Tuesday . The stock traded as high as $169.00 and last traded at $167.50, with a volume of 825,819 shares changing hands. The stock had previously closed at $156.74.

Several equities research analysts recently issued reports on ICPT shares. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, June 1st. Goldman Sachs Group Inc. raised their target price on shares of Intercept Pharmaceuticals from $114.00 to $128.00 and gave the company a “neutral” rating in a research note on Tuesday, May 31st. Laidlaw downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and cut their price objective for the stock from $345.00 to $105.00 in a research report on Friday, August 5th. Robert W. Baird restated an “outperform” rating and set a $332.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, June 1st. Finally, Wedbush restated an “outperform” rating and set a $239.00 price objective (down from $423.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, May 31st. Five analysts have rated the stock with a sell rating, five have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $177.67.

The company has a 50-day moving average price of $158.02 and a 200 day moving average price of $146.79. The firm’s market cap is $4.10 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/intercept-pharmaceuticals-inc-icpt-trading-up-6-9.html

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.69) by $0.55. The company had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. Intercept Pharmaceuticals’s revenue was up 1140.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.99) EPS. Equities research analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current year.

In related news, insider Lisa Bright sold 246 shares of the company’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $159.00, for a total transaction of $39,114.00. Following the sale, the insider now directly owns 18,460 shares in the company, valued at approximately $2,935,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mark Pruzanski sold 714 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total transaction of $103,608.54. The disclosure for this sale can be found here. Corporate insiders own 9.20% of the company’s stock.

Several hedge funds have recently made changes to their positions in ICPT. Norges Bank purchased a new stake in Intercept Pharmaceuticals during the fourth quarter valued at about $18,351,000. Aperio Group LLC boosted its stake in Intercept Pharmaceuticals by 31.2% in the first quarter. Aperio Group LLC now owns 2,152 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 512 shares in the last quarter. BlackRock Inc. boosted its stake in Intercept Pharmaceuticals by 301.5% in the first quarter. BlackRock Inc. now owns 1,915 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 1,438 shares in the last quarter. BlackRock Group LTD boosted its stake in Intercept Pharmaceuticals by 20.1% in the first quarter. BlackRock Group LTD now owns 13,074 shares of the biopharmaceutical company’s stock valued at $1,680,000 after buying an additional 2,188 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its stake in Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock valued at $60,030,000 after buying an additional 31,289 shares in the last quarter. Institutional investors own 81.86% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.